ArticleClinical & translational immunology2025
Coexistence of SAPHO syndrome and IgG4-related disease with Upadacitinib.
Article in Clinical & translational immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: To describe the first reported case of coexisting Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) syndrome and IgG4-related disease (IgG4-RD) and to evaluate the therapeutic response to Upadacitinib. Methods: We described the clinical course, investigations, treatments, and outcomes of a 45-year-old woman initially diagnosed with SAPHO syndrome who subsequently developed IgG4-RD. Laboratory tests, imaging findings, and therapeutic responses were analyzed. Results: The patient developed IgG4-RD-related organ involvement during the course of SAPHO syndrome. Although glucocorticoid therapy was initially effective, disease flares occurred upon tapering. Upadacitinib was initiated as an escalation therapy, leading to rapid improvement in clinical symptoms and normalization of inflammatory and IgG4-related serological markers. Sustained remission was maintained with continued treatment. Conclusion: This case demonstrates that Upadacitinib may be an effective therapeutic option for patients with concurrent SAPHO syndrome and IgG4-RD. The observed clinical response supports the potential role of JAK-STAT pathway modulation in managing overlapping immune-mediated disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.